{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Retrospective study for free flap reconstructions (2019 to 2022, tertiary referral center)."
      },
      "Participants": {
        "score": 1,
        "evidence": "tertiary referral center"
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to identify factors preventing complications to support clinical decision\u2010making."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "30\u2010day CFS was 63%."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 125 identified cases"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "female gender (HR: 9.4, CI: 2.6\u201333.5), alcohol abuse (HR: 3.5, CI: 1.4\u20138.4), N2\u20103 (HR: 2.4, CI: 1.3\u20134.4), obesity (HR: 2.1, CI: 0.9\u20135.1), preoperative anticoagulation (HR: 2.5, CI: 1.1\u20135.9)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Common complications were wound healing disorders (10.9%), hematoma (10%), total (7.3%) or partial (1.8%) flap necrosis, cardiovascular events (5.5%), and pulmonary artery embolism (4.5%)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  },
  "model": "gpt-4o"
}